Intention-to-prevent analyses for estimating human papillomavirus vaccine efficacy in clinical studies
Authors:
Open Access
- 1 September 2017
- journal article
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 7, 189-193
Abstract
No abstract availableKeywords
Funding Information
- Merck & Co., Inc.
This publication has 20 references indexed in Scilit:
- Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccineContemporary Clinical Trials, 2015
- A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in WomenNew England Journal of Medicine, 2015
- The Australian Experience With the Human Papillomavirus VaccineClinical Therapeutics, 2014
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide studyThe Lancet Oncology, 2010
- Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young WomenJNCI: Journal of the National Cancer Institute, 2010
- Age‐Specific Prevalence, Incidence, and Duration of Human Papillomavirus Infections in a Cohort of 290 US MenThe Journal of Infectious Diseases, 2008
- Genital Human Papillomavirus Infection in Men: Incidence and Risk Factors in a Cohort of University StudentsThe Journal of Infectious Diseases, 2007
- Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting InfectionJAMA, 2007
- Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialThe Lancet, 2007
- Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital DiseasesNew England Journal of Medicine, 2007